Market Assessment

Strategic Decisions for Investing or Divesting into an Oncological Asset
Objective :

Evaluation of the market potential of the asset gained through the acquisition

Problem Statement:

A global pharmaceutical company wished to evaluate the market value of an asset obtained by acquiring a mid-cap company. The new class of drug showed the potential in targeting multiple tumors in combination with their in-house immune checkpoint inhibitor (CPI). The assessment formed the basis of their decision to either retain or divest the product later.

Our Methodology:
  • Extensive Secondary Research
  • Extensive Primary Research
  • Competitive Benchmarking
  • Clinical Trials Analysis
  • Strategic Insights on Companies
  • Forecasting
  • Executive analysis, Information on therapy area, disease overview, unmet need, treatment algorithm, market drivers and barriers & SWOT analysis of the product/Indication
  • Competitive landscape for marketed and pipeline products
  • Detailed attribute analysis of the key competitor products
  • Market size in terms of value and volume of marketed and pipeline products
  • Detailed forecast for the acquired asset of interest and our final recommendation on investing/divesting

Related Insights

In-Licensing Opportunity
In-Licensing Opportunity

A large client based in USA, involved in drug delivery devices, with effective marketing and commercialization presence across the globe [...]

View Case
Out-Licensing Opportunity
Out-Licensing Opportunity

A Small Pharmaceutical Client Based At Sweden, Europe With Capabilities Around A Neonatal Mesenchymal Cells Involved DelveInsight [...]

View Case
Launch Landscape Analysis
Launch Landscape Analysis

A mid pharma client based in Germany, involved in late-stage development of a therapy for PID, with effective marketing [...]

View Case

Fill the form to download the case study

I consent to DelveInsight gathering details provided via this form. Check our Privacy Policy to know more.